Generic Byvalson Availability
Byvalson is a brand name of nebivolol/valsartan, approved by the FDA in the following formulation(s):
BYVALSON (nebivolol hydrochloride; valsartan - tablet;oral)
-
Manufacturer: FOREST LABS LLC
Approval date: June 3, 2016
Strength(s): EQ 5MG BASE;80MG
Has a generic version of Byvalson been approved?
No. There is currently no therapeutically equivalent version of Byvalson available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Byvalson. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions comprising nebivolol
Patent 7,803,838
Issued: September 28, 2010
Inventor(s): Davis; Eric & O'Donnell; John & Bottini; Peter
Assignee(s): Forest Laboratories Holdings Limited
Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.Patent expiration dates:- August 29, 2026✓
- August 29, 2026
-
Compositions comprising nebivolol
Patent 7,838,552
Issued: November 23, 2010
Inventor(s): Davis; Eric & O'Donnell; John P. & Bottini; Peter Bruce & Shaw; Andrew & Mason; R. Preston
Assignee(s): Forest Laboratories Holdings Limited
Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.Patent expiration dates:- October 4, 2027✓
- October 4, 2027
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- June 3, 2019 - NEW COMBINATION
More about Byvalson (nebivolol / valsartan)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: miscellaneous antihypertensive combinations
Consumer resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
